申请人:AstraZeneca AB
公开号:US20160376287A1
公开(公告)日:2016-12-29
Provided are a series of novel pyridine or pyrimidine derivatives which inhibit CDK9 and may be useful for the treatment of hyperproliferative diseases. In particular the compounds are of use in the treatment of proliferative disease such as cancer including hematological malignancies such as acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, diffuse large B cell lymphoma, Burkitt's lymphoma, follicular lymphoma and solid tumors such as breast cancer, lung cancer, neuroblastoma and colon cancer.
提供了一系列新颖的吡啶或嘧啶衍生物,可以抑制CDK9,并可能对治疗过度增殖性疾病有用。特别是这些化合物在治疗增殖性疾病方面具有用途,如癌症,包括血液恶性肿瘤,如急性髓细胞白血病,多发性骨髓瘤,慢性淋巴细胞白血病,弥漫性大B细胞淋巴瘤,Burkitt淋巴瘤,滤泡性淋巴瘤以及实体肿瘤,如乳腺癌,肺癌,神经母细胞瘤和结肠癌。